Close Menu

Beckman Coulter

The Australian firm has taken aim at several firms in the research, molecular diagnostics, and agricultural genomics fields for allegedly infringing its patent covering methods of analyzing non-coding DNA sequences.

The Olympus Diagnostics business that Beckman Coulter acquired last summer provided a $120 million contribution for the fourth quarter. The firm beat analysts' consensus estimate, despite a drag from cash instrument sales during the quarter.

The firm will pay a dividend of $.18 per share and plans to buy back up to 1.5 million shares of its outstanding common stock.

The new service, which is available worldwide, expands Beckman Coulter Genomics' DNA sequencing applications portfolio and makes use of Genpathway's experience with chromatin immunoprecipitation.

The alliance will combine Beckman Coulter Genomics' sequencing capabilities with Genpathway's ChIP sequencing data and analysis.

The cuts follow a round of layoffs at the same facility late last year.

The automated benchtop system, called SPRIworks Fragment Library System I, is scheduled to be launched this quarter. It is capable of preparing up to 10 DNA libraries for the Illumina Genome Analyzer within five hours, according to Beckman.

A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.

The upgrade comes a few weeks after Beckman Coulter issued preliminary 2010 EPS guidance.

GE Healthcare charges in its complaint that kits and instruments sold by Beckman Coulter Genomics based on the Agencourt Solid Phase Reversible Immobilization, or SPRI, technology "contain instructions to use the products in a manner that infringes one or more claims of the '231 and/or '946 patents."


Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.